These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 31482226

  • 1. Population pharmacokinetics of siltuximab: impact of disease state.
    Nikanjam M, Yang J, Capparelli EV.
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
    [Abstract] [Full Text] [Related]

  • 2. Clinical development of siltuximab.
    Davis CC, Shah KS, Lechowicz MJ.
    Curr Oncol Rep; 2015 Jul; 17(7):29. PubMed ID: 25986720
    [Abstract] [Full Text] [Related]

  • 3. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.
    Oncotarget; 2015 Oct 06; 6(30):30408-19. PubMed ID: 26327301
    [Abstract] [Full Text] [Related]

  • 4. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C.
    Lancet Oncol; 2014 Aug 06; 15(9):966-74. PubMed ID: 25042199
    [Abstract] [Full Text] [Related]

  • 5. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
    Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F.
    Clin Cancer Res; 2013 Jul 01; 19(13):3659-70. PubMed ID: 23659971
    [Abstract] [Full Text] [Related]

  • 6. Dose selection of siltuximab for multicentric Castleman's disease.
    Mayer CL, Xie L, Bandekar R, Qi M, van de Velde H, Reddy M, Qin X, Davis HM, Puchalski TA.
    Cancer Chemother Pharmacol; 2015 May 01; 75(5):1037-45. PubMed ID: 25784388
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects.
    Xu C, Han C, Marini J, Ford J, Marciniak S, Lopez M, Frederick B, de Vries D, Bandekar R, Davis HM, Zhou H, Puchalski TA.
    Clin Pharmacol Drug Dev; 2014 Jul 01; 3(4):328-34. PubMed ID: 27128840
    [Abstract] [Full Text] [Related]

  • 9. Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    Vernon M, Robinson D, Trundell D, Ishak J, Jen MH, Brazier J.
    Curr Med Res Opin; 2016 Jul 01; 32(7):1193-200. PubMed ID: 26972925
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
    Morra DE, Pierson SK, Shilling D, Nemat S, Appiani C, Guilfoyle M, Tendler C, van Rhee F, Fajgenbaum DC.
    Br J Haematol; 2019 Jan 01; 184(2):232-241. PubMed ID: 30203839
    [Abstract] [Full Text] [Related]

  • 12. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing.
    Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV.
    Cancer Chemother Pharmacol; 2015 Mar 01; 75(3):495-503. PubMed ID: 25557868
    [Abstract] [Full Text] [Related]

  • 13. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, Gibson D, Kanhai K, Kurzrock R.
    Lancet Haematol; 2020 Mar 01; 7(3):e209-e217. PubMed ID: 32027862
    [Abstract] [Full Text] [Related]

  • 14. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
    Min GJ, Jeon YW, Park SS, Park S, Shin SH, Yahng SA, Yoon JH, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Kim HJ, Min CK, Kim DW, Lee JW, Cho SG.
    Korean J Intern Med; 2021 Mar 01; 36(2):424-432. PubMed ID: 32088937
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
    van Rhee F, Rothman M, Ho KF, Fleming S, Wong RS, Fosså A, Dispenzieri A, Cavet J, Munshi N, Vermeulen J, Casper C.
    Patient; 2015 Apr 01; 8(2):207-16. PubMed ID: 25736164
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL, Floret S, Bentzen C.
    Br J Clin Pharmacol; 2004 Aug 01; 58(2):142-55. PubMed ID: 15255796
    [Abstract] [Full Text] [Related]

  • 18. Frontline Siltuximab and Rituximab in TAFRO syndrome: A case report.
    Marchetti M, Feyles E, Zinzani P.
    Eur J Haematol; 2020 Oct 01; 105(4):505-507. PubMed ID: 32564425
    [No Abstract] [Full Text] [Related]

  • 19. Siltuximab: a new option for the management of Castleman's disease.
    Barquero N.
    Drugs Today (Barc); 2015 Jan 01; 51(1):21-8. PubMed ID: 25685858
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S, Jansen M, Matsushima N, Chen S, Mendell J.
    Cancer Chemother Pharmacol; 2016 May 01; 77(5):987-96. PubMed ID: 27017616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.